Therefore, A growing number of these agents, such as DNMT inhibitors (e.g., azacitidine), HDAC inhibitors (e.g., vorinostat), and EZH2 inhibitors (e.g., tazemetostat), have received regulatory approval from the Food and Drug Administration (FDA) and other international agencies for the treatment of hematologic malignancies and solid tumors, reflecting the therapeutic promise of this class of drugs, as summarized in Table 1. Here, DNMT1 is linked to hematologic disorder.